2023 SABCS | Laekna Reports Afuresertib Phase Ib Breast Cancer Study Results ...Middle East

PR Newswire - News
2023 SABCS | Laekna Reports Afuresertib Phase Ib Breast Cancer Study Results
- A multi-center phase Ib/III study in China and the United States led by Professor Binghe Xu, MD, PhD, Academician of the Chinese Academy of Engineering - 70% of the patients enrolled in phase Ib study were previously treated with CDK4/6 inhibitors - Demonstrated a confirmed objective...

Hence then, the article about 2023 sabcs laekna reports afuresertib phase ib breast cancer study results was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( 2023 SABCS | Laekna Reports Afuresertib Phase Ib Breast Cancer Study Results )

Apple Storegoogle play

Last updated :

Also on site :